Elevation Point Wealth Partners LLC Invests $1.66 Million in Edwards Lifesciences Corporation $EW

Elevation Point Wealth Partners LLC purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,295 shares of the medical research company’s stock, valued at approximately $1,655,000.

Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter worth $5,318,092,000. Norges Bank bought a new position in shares of Edwards Lifesciences during the 4th quarter worth $803,686,000. Conway Capital Management Inc. purchased a new position in shares of Edwards Lifesciences during the second quarter valued at $954,000. TD Asset Management Inc increased its stake in shares of Edwards Lifesciences by 6.4% during the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after buying an additional 47,051 shares during the period. Finally, Intech Investment Management LLC raised its holdings in shares of Edwards Lifesciences by 22.2% in the fourth quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company’s stock valued at $5,912,000 after acquiring an additional 12,591 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on EW. UBS Group started coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They set a “buy” rating and a $110.00 target price on the stock. Citigroup upped their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Mizuho increased their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Truist Financial boosted their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Finally, Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their target price for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Stock Performance

Shares of EW opened at $89.89 on Monday. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The firm has a market cap of $51.76 billion, a PE ratio of 51.66, a P/E/G ratio of 2.25 and a beta of 0.85. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The stock has a fifty day moving average price of $89.21 and a 200-day moving average price of $84.68.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 25,570 shares of company stock valued at $2,219,390. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.